Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
STARD13 encodes a protein which contains an N-terminal sterile alpha motif (SAM) for protein-protein interactions, followed by an ATP/GTP-binding motif, a GTPase-activating protein (GAP) domain, and a C-terminal STAR-related lipid transfer (START) domain.
Showing 2 out of 2 products:
Low STARD13 expression is associated with metastasis of breast cancer.
miR (zeige MLXIP ELISA Kits)-125b functions as an oncogene (zeige RAB1A ELISA Kits) in gastric cancer and represents a new potential therapeutic target for gastric cancer.
The tumor suppressor DLC2 and Kif1B are central components of a signaling network that guides spindle positioning, cell-cell adhesion and mitotic fidelity.
Dimerization of DLC2 was required for its interaction with GKAP, which, in turn, potentiated GKAP self-association.
Study describes STARD13 as a tumor suppressor playing a positive role in cancer motility.
The present study further describes the role of StarD13 as a tumor suppressor as well as a Rho GAP.
Importance of the regulation of RhoA (zeige RHOA ELISA Kits) activity in focal adhesions of astrocytoma cells and StarD13 is a GAP playing a major role in this process.
In the present review, we discuss the family of RhoGTPases, their regulation and their RhoGAPs, focusing mainly on STARD13. [review]
RhoGAP protein Stard13 is an essential regulator of pancreas tissue architecture in the mammalian embryo; Stard13 acts by regulating Rho signalling spatially and temporally during pancreas development.
Authors detected an increase in p-ERK (zeige EPHB2 ELISA Kits) in StarD13 knockdown cells, uncovering a potential link between Rho GTPases and ERK (zeige EPHB2 ELISA Kits) activation.
role of miR (zeige MLXIP ELISA Kits)-125b in pro-metastasis by targeting STARD13
DLC2 plays a key role in pain modulation during inflammation by suppressing the activation of RhoA (zeige RHOA ELISA Kits) and ERK (zeige EPHB2 ELISA Kits) to prevent an exaggerated pain response
Results suggest that DLC2 exhibits its tumor suppressor functions in vivo as a GAP specific for RhoA (zeige RHOA ELISA Kits), exerting its effects in suppression of cytoskeleton reorganization, cell growth, cell migration, and transformation.
This gene encodes a protein which contains an N-terminal sterile alpha motif (SAM) for protein-protein interactions, followed by an ATP/GTP-binding motif, a GTPase-activating protein (GAP) domain, and a C-terminal STAR-related lipid transfer (START) domain. It may be involved in regulation of cytoskeletal reorganization, cell proliferation, and cell motility, and acts as a tumor suppressor in hepatoma cells. The gene is located in a region of chromosome 13 that is associated with loss of heterozygosity in hepatocellular carcinomas. Alternatively spliced transcript variants encoding different isoforms have been described for this gene.
, Rho GTPase activating protein on chromosome 13q12
, deleted in liver cancer 2 protein
, long intergenic non-protein coding RNA 464
, stAR-related lipid transfer protein 13
, START domain-containing protein 13
, serologically defined colon cancer antigen 13
, serologically defined colon cancer antigen 28
, StAR-related lipid transfer (START) domain containing 13